In conclusion, inhibition via targeting CAMs intravitreally in other retinal disorders such as AMD and DME illustrated the potential to serve as primary or adjunct therapy to anti-vascular endothelial growth factor agents. This evidence concerns the gene VEGFA and retinal disorder.